Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04762602 2026-03-27

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Phase 1 Terminated

42 enrolled 26 charts

CNSGastrointestinal

Glioma, Cholangiocarcinoma

NCT04380753 2026-03-25

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Phase 1 Completed

12 enrolled 12 charts

Other solid neoplasm

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

Clinical Trials

First in Human Study of M1069 in Advanced Solid Tumors

Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact

BOOST

Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

PEACH

Phase Ib of L-NMMA and Pembrolizumab

MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer

TAS3351

Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).